BGB-11417-301 Protocol title: A Phase 3 Open-Label Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Brief description of study

BGB-11417-301 Protocol title: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia


Clinical Study Identifier: s23-01577
ClinicalTrials.gov Identifier: NCT06073821
Principal Investigator: Catherine M Diefenbach.
Other Investigators: Kenneth B Hymes, Bruce G Raphael, Michael L. Grossbard, Kathryn Dowling, Tibor Moskovits, Ellaine R Yap.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.